Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SGLT2 inhibitors with metformin look safe for bone

Publish date:: August 19, 2020

Key clinical point: SGLT2 inhibitors were linked to a heightened risk in previous observational studies.

Major finding: No significant increase in fracture rate was found in type 2 diabetes patients taking SLGT-2 inhibitors plus metformin.

Study details: Meta-analysis of 25 trials in 19,500 subjects.

Disclosures: The authors did not disclose any funding and had no relevant conflicts of interest.

Citation:

B-B Qian et al. Osteoporosis Int. 2020 Aug 11. doi: 10.1007/s00198-020-05590-y.

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Must Reads in Osteoporosis

Oral steroids plus PPIs increase osteoporotic fracture risk in RA patients,

Denosumab favored over alendronate for BMD protection in glucocorticoid-induced osteoporosis,

Treatment sequence with romosozumab influences osteoporosis outcomes,

CagA-positive H. pylori patients at higher risk of osteoporosis, fracture,

SGLT2 inhibitors with metformin look safe for bone,